Ghrelin and GHRH Pathways
Ipamorelin and CJC-1295 (No DAC) are two growth hormone secretagogue research peptides that act through complementary but distinct receptor systems. Ipamorelin is a growth hormone-releasing peptide (GHRP) that engages the ghrelin receptor, also known as the growth hormone secretagogue receptor (GHS-R). CJC-1295 is an analog of growth hormone-releasing hormone (GHRH) that engages the separate GHRH receptor. The comparison is therefore between two different upstream mechanisms within the same broad secretagogue category.
Because the two peptides act on different receptors, the research literature frequently studies them together to observe how GHRP and GHRH-analog signaling behave in combination. This article frames both compounds strictly by receptor target, molecular class, and research context, with no claims about efficacy, dosing, or outcomes in humans or animals. For broader context on this compound class, see the growth hormone secretagogues pillar overview. Both are supplied for research use only, not for human or animal consumption.
Recommended Products
Mechanistic Comparison
The table below contrasts the receptor targets and research framing of these two secretagogue peptides.
| Compound | Class | Receptor Target | Research Focus |
|---|---|---|---|
| Ipamorelin | GHRP (secretagogue) | Ghrelin receptor (GHS-R) | Ghrelin-pathway signaling |
| CJC-1295 (No DAC) | GHRH analog | GHRH receptor | GHRH-pathway signaling |
Ipamorelin is a selective GHRP that binds the ghrelin receptor. It is noted in the research literature for its selectivity, and it is studied as a tool for isolating ghrelin-receptor signaling within the broader secretagogue system. Its mechanism centers on this single, well-defined receptor.
CJC-1295 (No DAC) is a modified GHRH analog that engages the GHRH receptor rather than the ghrelin receptor. The GHRH receptor sits on a different signaling pathway, and the No DAC variant is characterized by a shorter functional profile compared with DAC-modified versions. As a GHRH-pathway tool, it is studied independently of ghrelin-receptor compounds.
The reason these two peptides are so often examined together is that their receptors are complementary rather than overlapping. GHRP and GHRH-analog signaling engage separate upstream receptors, and researchers investigate how simultaneous activation of both pathways compares with activation of either one alone. This synergistic study design treats Ipamorelin and CJC-1295 as parallel inputs into the growth hormone secretagogue axis, each contributing through a distinct receptor. Because the mechanisms are separate, the comparison highlights pathway complementarity rather than a difference in receptor count. All statements here are limited to documented receptor mechanisms and molecular class.
Combined-Use Research Context
Selection depends on which pathway a study targets. Research into ghrelin-receptor signaling calls for Ipamorelin, while GHRH-pathway work uses CJC-1295 (No DAC). Because their receptors are complementary, many study designs examine the two in parallel to characterize how the pathways interact.
Proper handling underpins reproducible secretagogue research. Lyophilized peptides should be stored cold, reconstituted with an appropriate solvent, and protected from repeated freeze-thaw cycles that degrade peptide integrity. Amino Labs provides third-party analytical documentation for each compound so researchers can verify identity and purity before parallel or combination studies. When two peptides are studied together, verified purity of each is essential to attributing observed signaling correctly. These products are for laboratory research use only and are not for human or animal consumption.